Bristol-Myers Squibb has announced a scientific cooperation agreement with biotech company Illumina, which produces DNA sequencers. The partnership is aimed at developing diagnostic tests to be combined to BMS’ cancer therapies and to determine new biomarkers. One of the first objectives of the cooperation will be determining how DNA varies in cancer cells as compared to healthy cells. The cooperation is pivotal to BMS, since developing new diagnostic tests has potential to result in more efficient novel drugs. Illumina is among the most robust companies in the whole Nasdaq, with a 50% growth over the last 12 months and a $35bn capitalization.
This is not the only good piece of news of the week for BMS. The US-based group, indeed, announced after trading closed that the Phase III CheckMate -078 clinical trial, assessing Opdivo (nivolumab) in a sample of Chinese patients with non-small cell lung cancer (NSCLC) has reached its primary endpoint and two secondary endpoints. Detailed results from the trials will be announced on Monday, April 16th, at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago.